Global Nicotine Replacement Therapy for Smoking Cessation Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Nicotine Replacement Therapy for Smoking Cessation Market Insights, Forecast to 2034
NRT, or Nicotine Replacement Therapy, refers to a range of smoking cessation aids that are designed to help individuals quit smoking by providing them with controlled doses of nicotine. NRT products are available in various forms, such as nicotine gum, patches, lozenges, nasal sprays, and inhalers. These aids work by delivering nicotine to the body without the harmful toxins and chemicals found in tobacco smoke, thereby reducing withdrawal symptoms and cravings associated with quitting smoking.
Market Analysis and InsightsGlobal Nicotine Replacement Therapy for Smoking Cessation Market
Global Nicotine Replacement Therapy for Smoking Cessation market is expected to reach to US$ 549 million in 2023, with a positive growth of %, compared with US$ 524 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Nicotine Replacement Therapy for Smoking Cessation industry is evaluated to reach US$ 727.3 million in 2033. The CAGR will be 4.8% during 2023 to 2033.
Globally, Nicotine Replacement Therapy for Smoking Cessation key companies include Pfizer, Cipla, Novartis, GlaxoSmithKline, Johnson & Johnson, Philip Morris, Perrigo Company, Alkalon and Ventus Medical, etc. Pfizer, Cipla, Novartis are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Nicotine Replacement Therapy for Smoking Cessation were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Nicotine Replacement Therapy for Smoking Cessation market and estimated to attract more attentions from industry insiders and investors.
Nicotine Replacement Therapy for Smoking Cessation can be divided into Sprays and Inhalers, Gums, Patches and Lozenges, etc. Sprays and Inhalers is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Nicotine Replacement Therapy for Smoking Cessation is widely used in various fields, such as Pharmacy, Supermarket, Hospital and Other, etc. Pharmacy provides greatest supports to the Nicotine Replacement Therapy for Smoking Cessation industry development. In 2022, global % revenue of Nicotine Replacement Therapy for Smoking Cessation went into Pharmacy filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Nicotine Replacement Therapy for Smoking Cessation market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Nicotine Replacement Therapy for Smoking Cessation market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Pfizer
Cipla
Novartis
GlaxoSmithKline
Johnson & Johnson
Philip Morris
Perrigo Company
Alkalon
Ventus Medical
Segment by Type
Sprays and Inhalers
Gums
Patches
Lozenges
Pharmacy
Supermarket
Hospital
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Nicotine Replacement Therapy for Smoking Cessation introduction, etc. Nicotine Replacement Therapy for Smoking Cessation Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Nicotine Replacement Therapy for Smoking Cessation
Chapter 13Methodology and Data Sources adopted by MRAResearch
Market Analysis and InsightsGlobal Nicotine Replacement Therapy for Smoking Cessation Market
Global Nicotine Replacement Therapy for Smoking Cessation market is expected to reach to US$ 549 million in 2023, with a positive growth of %, compared with US$ 524 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Nicotine Replacement Therapy for Smoking Cessation industry is evaluated to reach US$ 727.3 million in 2033. The CAGR will be 4.8% during 2023 to 2033.
Globally, Nicotine Replacement Therapy for Smoking Cessation key companies include Pfizer, Cipla, Novartis, GlaxoSmithKline, Johnson & Johnson, Philip Morris, Perrigo Company, Alkalon and Ventus Medical, etc. Pfizer, Cipla, Novartis are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Nicotine Replacement Therapy for Smoking Cessation were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Nicotine Replacement Therapy for Smoking Cessation market and estimated to attract more attentions from industry insiders and investors.
Nicotine Replacement Therapy for Smoking Cessation can be divided into Sprays and Inhalers, Gums, Patches and Lozenges, etc. Sprays and Inhalers is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Nicotine Replacement Therapy for Smoking Cessation is widely used in various fields, such as Pharmacy, Supermarket, Hospital and Other, etc. Pharmacy provides greatest supports to the Nicotine Replacement Therapy for Smoking Cessation industry development. In 2022, global % revenue of Nicotine Replacement Therapy for Smoking Cessation went into Pharmacy filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Nicotine Replacement Therapy for Smoking Cessation market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Nicotine Replacement Therapy for Smoking Cessation market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Pfizer
Cipla
Novartis
GlaxoSmithKline
Johnson & Johnson
Philip Morris
Perrigo Company
Alkalon
Ventus Medical
Segment by Type
Sprays and Inhalers
Gums
Patches
Lozenges
Segment by Application
Pharmacy
Supermarket
Hospital
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Nicotine Replacement Therapy for Smoking Cessation introduction, etc. Nicotine Replacement Therapy for Smoking Cessation Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Nicotine Replacement Therapy for Smoking Cessation
Chapter 13Methodology and Data Sources adopted by MRAResearch